NCT07117890RecruitingPhase 2
Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
a Study of Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
Source: ClinicalTrials.gov · Last updated 24 Dec 2025
Brief summary (registry, in English)
This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- First submitted
- 5 Aug 2025
- Start date
- 7 Feb 2025
- Primary completion date
- 20 Feb 2027
- Lead sponsor
- Fudan University
- Diseases
- Lung cancer
- NCT number
- NCT07117890
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 34
- From 7 Feb 2025 to the primary completion date, 20 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previos systemic anti-tumor therapy
Other illness
- a history of malignant tumors within 2years
- any severa or poorly controlled systemic disease per investigator's judgement
- active infections
Who the study is looking for
- ≥18 years old
- histologically or cytologically confirmed non-squamous NSCLC with documented EGFR uncommon mutations from a local laoratory. at least one EGFR uncommon mutation (excluding EGFR 19del/l858r/T790m/Ex 20ins ) or compund mutations with EGFR uncommon mutations.
- predicted life expectancy ≥ 12 weeks.
- patient must have measurable disease according to RECIST 1.1
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.